Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled ‘A Phase 1/2A Dose ...

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today reported financial results for the second ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...